Yi, Zongyi
Zhao, Yanxia
Yi, Zexuan
Zhang, Yongjian
Tang, Gangbin
Zhang, Xiaoxue
Tang, Huixian
Zhang, Wei
Zhao, Ying
Xu, Huayuan
Nie, Yuyang
Sun, Xueqing
Xing, Lijun
Dai, Lian
Yuan, Pengfei
Wei, Wensheng http://orcid.org/0000-0002-8053-2423
Article History
Received: 1 February 2023
Accepted: 9 October 2023
First Online: 23 October 2023
Declarations
:
: All NHP studies were accredited by AAALAC International (Association for Assessment and Accreditation of Laboratory Animal Care International). The content and procedures related to animal testing are in accordance with the regulations of the Institutional Animal Care and Use Committee (IACUC) and the 8th Edition of the Institute of Laboratory Animal Resources, National Research Council, 2011. There were no alternatives to this test, and the test was not repeated. Animal numbers were designed according to the appropriate guidelines. This experiment has been approved by the Institutional IACUC of WestChina-Frontier Pharmatech Co., Ltd., approval number: IACUC-B2021025-T005-01, IACUC-B2021025-T005-02, IACUC-B2021025-T005-03, IACUC-B2021025-T005-04, IACUC-B2021025-T005-05. The mouse experiments were approved by the Peking University Laboratory Animal Center (Beijing) and undertaken in accordance with the National Institutes of Health Guide for Care and Use of Laboratory Animals.
: A patent has been filed relating to the data presented. P.Y. and Y.Z. are coinventors on patent applications describing circ-arRNA targeting human IDUA W402X mutation. P.Y., Y.Z., Zexuan Yi., G.T., Yongjian Zhang, W.Z., Ying Zhao, H.X., Y.N., X.S., L.X., and L.D. are employees of EdiGene Inc. W.W. is a founder and scientific advisor for EdiGene, Inc. The other authors declare no competing interests.